Hasil Guna L-ornitin L-aspartat Intravena Dibanding Plasebo terhadap Penurunan Kadar Amonia Darah pada Penderita Ensefalopati Hati  

Oleh:

Syahrizal ; Nurdjanah, Siti ; Maduseno, Sutanto

Jenis: Article from Journal - ilmiah nasional
Dalam koleksi: Berkala Kesehatan Klinik vol. 15 no. 01 (Jun. 2009), page 1-6 .
Topik: Hepatic Encephalopathy-ammonia-LOLA

Ketersediaan

Perpustakaan FK Nomor Panggil: B25.K.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Background: Patients with chronic hepatitis often develop neurologic problems, the most common of which is hepatic encephalopathy (HE). Increase in the blood ammonia level is assumed to be the primary cause of HE. Ammonia works as the neurotransmission inhibitor on gamma¬amino butyric acid (GABA) receptor at central nervous system. L -Ornithine-L-Aspartate (LOLA) is a form of ornithine amino acid and aspartate acid that may reduce the level of blood ammonia by stimulating urea cycle and glutamine synthesis, which play crucial roles in ammonia detoxification mechanism. Objective: This study investigates whether addition of LOLA in standard treatment able to reduce blood ammonia level significantly as compared with standard treatment pius placebo. Methods: This is a queasy experimental study that involves 50 hepatic encephalopathy patients which is divided into two groups. Treatment group is treated with standard treatment plus administration of intravenous LOLA is conducted within three days whereas placebo group is treated with standard treatment plus placebo. Mean difference of ammonia level in LOLA group before and after the therapy compared to those in placebo group before and after the therapy are tested for their significance with unpaired t-test. Result and Conclusion: It is found that the mean difference in the ammonia level for both group is not different significantly (p = 0.846, 95% CI= -50.63 - 61.44 ).The study concludes that there is no significant difference in the reduction of blood ammonia level (NH3) among cirrhosis hepatic patients with hepatic encephalopathy who receive LOLA and those who receive placebo.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali